Zaraket H, Hurt AC, Clinch B, Barr I, Lee N. Burden of influenza B virus infection and considerations for clinical management. Antiviral Res. 2020 Nov 4:104970
Influenza B viruses cause significant morbidity and mortality, particularly in children, but the awareness of their impact is often less than influenza A viruses partly due to their lack of pandemic potential. Here, we summarise the biology, epidemiology and disease burden of influenza B, and review existing data on available antivirals for its management. There has long been uncertainty surrounding the clinical efficacy of neuraminidase inhibitors (NAIs) for influenza B treatment. In this article, we bring together the existing data on NAIs and discuss these alongside recent large randomised controlled trial data for the new polymerase inhibitor baloxavir in high-risk influenza B patients. Finally, we offer considerations for the clinical management of influenza B, with a focus on children and high-risk patients where disease burden is highest.
See Also:
Latest articles in those days:
- Development and application of a real-time RT-PCR assay to rapidly detect H2 subtype avian influenza A viruses 2 days ago
- Epigraph hemagglutinin vaccine induces broad cross-reactive immunity against swine H3 influenza virus 2 days ago
- Human Infection with Eurasian Avian-Like Swine Influenza A(H1N1) Virus, the Netherlands, September 2019 2 days ago
- Influenza A virus surveillance, infection, and antibody persistence in snow geese (Anser caerulescens) 3 days ago
- A Live Attenuated H9N2 Avian Influenza Vaccine Prevents the Viral Reassortment by Exchanging the HA and NS1 Packaging Signals 5 days ago
[Go Top] [Close Window]